Clover Health Investments, Corp. — Form 8-K Summary
Business Context and Reporting Period
Filed August 28, 2023, under Item 8.01 (Other Events). The filing concerns the Company’s Nasdaq listing compliance and a previously scheduled special stockholder meeting; it does not report quarterly or annual operating results.
Key Financial Metrics and Capital Structure
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial performance figures. Clover Health’s Class A common stock trades on Nasdaq under the symbol CLOV.
Material Changes Versus the Prior Comparable Period
- Nasdaq notified the Company on July 31, 2023 that it had regained compliance with Nasdaq’s minimum bid price requirement.
- Because compliance was regained, the Company no longer intends to pursue the proposed reverse stock split or authorized share reduction at this time.
- The special stockholder meeting scheduled for August 30, 2023, at 11:00 a.m. Eastern Time was cancelled.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance or operating outlook. It includes customary cautionary language stating that forward-looking statements are subject to risks and uncertainties and may differ materially from actual results. Investors are directed to the risk factors in the Company’s Form 10-K filed March 1, 2023, and Forms 10-Q filed May 9, 2023 and August 8, 2023.
Facts Investors Should Verify
- Confirm the Company’s continued compliance with Nasdaq’s minimum bid price requirement.
- Verify that the proposed reverse stock split and authorized share reduction remain deferred or are otherwise addressed in subsequent filings.
- Review subsequent SEC filings for any rescheduled stockholder meeting, capital structure changes, or new Nasdaq compliance notices.
- Consult the cited 10-K and 10-Q filings for financial metrics, liquidity, debt, and material risk disclosures not included in this 8-K.